On February 28 and March 1, 2026, São Paulo hosted the 10th edition of the Thyroid Cancer International Meeting, one of Brazil’s leading medical events dedicated to thyroid cancer. The meeting brought together national and international experts at the Sheraton São Paulo WTC Hotel, with a program focused on scientific updates, evidence-based practice, and the latest advances in the diagnosis and treatment of malignant thyroid tumors.
Since its conception, the event has been supported by LATS, fostering excellent interaction among endocrinologists, surgeons, oncologists, and other healthcare professionals. This collaboration strengthened regional cooperation and contributed to the development of clinical care protocols. The presence of internationally recognized opinion leaders and experts in endocrine oncology reinforced the importance of the meeting within the Latin American medical agenda.
The scientific program featured outstanding lectures from internationally renowned specialists:
Professor Michael Tuttle
- The centimeter mark or the intrathyroidal tumor: What’s the new cornerstone to define low-risk tumors?
- Isthmus carcinomas: Are we facing “the ugly” low-risk PTC?
- Lobectomy in “aggressive” variants of papillary carcinoma
Professor Laura Boucai
- Defining the Suspicious Nodule according to the new ATA Guidelines
- Defining Response to Treatment of DTC using Thyroglobulin and Imaging in accordance with the new ATA Guidelines
- What is the ideal TSH level after lobectomy? Why do we continue to use the same TSH range goal as before?
Professor Michael Yeh (USA)
- Prognostic factors not to miss the actual Intermediate Risk
- How Artificial Intelligence is Changing Thyroid Nodule Diagnostics
- Lobectomy in follicular carcinoma and oncocytic cell carcinoma
Professor Gregory Randolph (USA)
- Nodal surgery in DTC: Preoperative assessment
- Revision surgery in DTC – Who is a candidate?
Dr. Gabrielle Materazzi (Italy)
- Micro MTC and Lobectomy
- To what extent is surgical treatment decisive for the patient’s cure?
Dr. Seza Gulec (USA)
- The New Era of RAI: Biology- and Dosimetry-Guided Therapy for Differentiated Thyroid Cancer
- Personalizing Surgery for DTC: Integrating Theranostic Risk Stratification and Differentiation Biology
- The New Era of RAI: Biology- and Dosimetry-Guided Therapy for Differentiated Thyroid Cancer
The 10th edition once again consolidated its role as a key platform for scientific exchange and innovation in thyroid cancer management.
